Navigation Links
ThermoGenesis Announces Reverse Stock Split Effective on NASDAQ Capital Market August 27, 2010
Date:8/26/2010

that includes the AXP and the MXP™ MarrowXpress™ and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting.
  • The Res-Q™ 60 BMC (Res-Q), a point-of-care system that is designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates.
  • The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community.

  • This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal years 2010 and 2011, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2010 and 2011. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk F
    '/>"/>

    SOURCE ThermoGenesis Corp.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program
    2. ThermoGenesis Names Jorge Artiles Vice President, Chief Quality and Regulatory Affairs Officer
    3. ThermoGenesis Announces National Institute of Health Grant
    4. ThermoGenesis Announces MXP Involvement in New Regenerative Medicine Initiatives
    5. Luminex Announces Commercial Launch of New Cystic Fibrosis Test
    6. CareFusion Announces National Launch of Spinal Fracture Device
    7. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
    8. Delcath Systems Announces Completion of Common Stock Offering
    9. Ambry Genetics Announces the Addition of Illumina HiSeq 2000 and First 510(K) Approved BeadXpress® to Its Sequencing and Genotyping Capabilities
    10. Veteran Affairs Announces That Redsense Alarm Will be Mandatory on Patients by November 1, 2010
    11. Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI® (epoprostenol for injection) for Pulmonary Arterial Hypertension
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... DIEGO, July 31, 2014 Tandem Diabetes Care®, Inc. ... manufacturer of the t:slim® Insulin Pump, today reported its financial ... In comparing the second quarter of 2014 to the ... to $10.3 million from $5.5 million , t:slim Pump ... In comparing six months ended June 30, 2014 ...
    (Date:7/31/2014)... SAN FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... the second quarter ended June 30, 2014. ... were $301.4 million as compared to $309.1 million at March ... time for Nektar as we look forward to significant milestones ... W. Robin, President and Chief Executive Officer of Nektar. "The ...
    (Date:7/31/2014)... SARASOTA, Fla. , July 31, 2014 ... announced today that it has initiated the development of ... ; and that it has selected Quotient Clinical, ... United Kingdom (UK) to run its early ... a Clinical Trial Application (CTA) by the end of ...
    Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
    ... class action lawsuit (Case #BC4241898) was just filed in Los ... Inc., and GE Healthcare Technologies on behalf of patients who ... brain perfusion scans to diagnose strokes. , Trevor Rees ... a Delaware Corporation; GE Healthcare Technologies, Inc., a corporation; and ...
    ... EAST RUTHERFORD, N.J., Oct. 20 Cambrex Corporation (NYSE: ... Silver Innovation Award at the 2009 CPhI Event for ... award was accepted by Dr. Jayne E. Muir (Market ... technology to a panel of judges at this important ...
    Cached Medicine Technology:Patients Receiving High Radiation at Cedars Sinai File Class Action Lawsuit 2Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award 2
    (Date:8/1/2014)... aesthetic injectable procedures have grown in popularity as more ... As Botulinum toxin generally known as BOTOX ... health professionals have emerged to perform procedures utilizing this ... Spinelli, MD from the Division of Plastic Surgery Presbyterian ... from Columbia University in New York have assessed the ...
    (Date:8/1/2014)... (PRWEB) August 01, 2014 With fast food ... and the convenience of processed, microwavable dinners, it is no ... does not offer patients a mere quick fix for shedding ... in any part of the country, get slimmer and healthier ... offer patients the tools and education on how to ...
    (Date:8/1/2014)... August 01, 2014 St. Christopher's Hospital ... an upcoming episode of Innovations with Ed Begley Jr, ... and show times TBA. , St. Christopher's Hospital for ... for children from birth through 21 years of age. ... of the hospital's specialties, including autism and childhood obesity. ...
    (Date:8/1/2014)... 01, 2014 For many people, forgetfulness ... is still within the normal range, slips that seem ... future decline. This merits a closer look, not a ... 2014 Harvard Men's Health Watch . , ... forget where their keys are they are on the ...
    (Date:8/1/2014)... 2014 Narconon Arrowhead recently celebrated the ... the drug rehab center located in the small town ... Arrowhead is the flagship drug rehab center in the ... States for services there. Now, with such a long ... studies as well as client reviews showing the effectiveness ...
    Breaking Medicine News(10 mins):Health News:Plastic surgeons or nurses: Who are the better injectors? 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 3Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:Worried About Changes in Your Memory? It's Worth A Closer Look, From the August 2014 Harvard Men's Health Watch 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 3
    ... spike between 2008 and 2009, analysis finds , SATURDAY, ... appear to be on the rise, warns the American ... and baseball/softball are the main culprits. , The cautionary ... as they transpired between 2008 and 2009, based on ...
    ... drinkers were 39% less likely to get these malignancies ... help protect against head and neck cancers, a new ... the International Head and Neck Cancer Epidemiology consortium. They ... a day) were 39 percent less likely to develop ...
    ... is part of being a good dad, expert suggests , ... dads unwrap their new ties and other tokens of gratitude, ... kind of gift: a promise that they,ll watch their health, ... On average, men die younger than women and are more ...
    ... radiation not always ideal for many with low risk ... -- For patients with prostate cancer that has a ... "watchful waiting," may be a suitable treatment option, according ... of how (or whether) to treat localized prostate cancer ...
    ... ... ... Technologies , the leading independent provider of search software integration services announced today an ... for the Folio and NXT professional publishing products. The Folio product family includes Folio ...
    ... Recent research has shown increase in sexual satisfaction, if ... A U.S. Food and Drug Administration advisory panel on ... the "female Viagra" for premenopausal women with a diminished ... to the antidepressant family and affects serotonin and other ...
    Cached Medicine News:Health News:Bump in Head Injury Numbers Linked to Summer Play 2Health News:On Father's Day, Give Dad Gift of Health 2Health News:'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer 2Health News:Search Technologies Partners with Rocket Software to Provide Expert Support for Folio and NXT Products 2Health News:Search Technologies Partners with Rocket Software to Provide Expert Support for Folio and NXT Products 3
    ... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep™ ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
    The SEDITAINER Erythrocyte Sedimentation Rate (ESR) System is for collection of blood specimens for the measurement of ESR within the blood collection tube, using the SEDITAINER ESR Stand....
    ... NMP22® Test Kit is a quantitative microplate enzyme ... are at risk for rapid recurrence or occult ... voided urine sample and is twice as sensitive ... to improve patient outcome by identifying those patients ...
    ... Unlike other ESR products, SEDIPLAST® ... superior design features to protect laboratory ... blood handling. SEDIPLAST® is a uniquely ... which provides greater safety and convenience ...
    Medicine Products: